UnitedHealth Group (UNH) has reportedly approached Aetna (AET) about a takeover deal valued at more than $40 billion, according to the Wall Street Journal, which is just the latest rumor amid a wave of speculation about consolidation among the big five managed-care companies. With Aetna (AET) itself and other insurers said to be interested in acquiring Humana (HUM) and Anthem (ANTM) in talks to buy smaller rival Cigna (CI), Vishnu Lekraj, equity analyst at Morningstar (MORN) reveals how likely it is that significant consolidation will occur and what it will mean for the industry. Lekraj says the likelihood of consolidation moving forward is very high, as these companies need to build scale and increase memberships in order to survive over the coming years. In terms of UnitedHealth and Aetna, Lekraj finds it a bit surprising that UnitedHealth is in the mix, being as it is the largest insurer in the U.S. with some of the most diversified memberships. He said UnitedHealth controls the market for the most part and he doesn't see the company under pressure to make a move here. However, he acknowledges that UnitedHealth could foresee some headwinds down the road if it doesn't make a move, especially with Anthem looking to buy one of the other three smaller managed-care companies.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.